Table 3 Adjusted HRs and 95% CIs for risk of specific-site cancer across the trajectories of life’s essential 8 scores in Kailuan study.

Head and neck cancer

Ref.

0.81 (0.58,1.13)

0.77 (0.51, 1.14)

0.366

Lung cancer

Ref.

0.86 (0.71, 1.04)

0.73 (0.57,0.92)

0.033

Breast cancer^a

Ref.

0.51 (0.35, 0.77)

0.49 (0.32, 0.77)

0.002

Kidney cancer

Ref.

1.30 (0.79, 2.13)

0.81 (0.43, 1.54)

0.171

Bladder cancer

Ref.

1.51 (0.83, 2.75)

1.20 (0.59, 2.42)

0.328

Prostatic cancer^a

Ref.

0.68 (0.39, 1.21)

0.80 (0.41, 1.58)

0.419

Esophageal cancer

Ref.

1.09 (0.62, 1.92)

1.26 (0.65, 2.44)

0.789

Stomach cancer

Ref.

0.77 (0.53, 1.12)

0.83 (0.53, 1.30)

0.391

Colorectal cancer

Ref.

0.81 (0.62, 1.06)

0.69 (0.50, 0.97)

0.093

Pancreatic cancer

Ref.

0.92 (0.46, 1.84)

0.99 (0.44, 2.23)

0.960

Liver cancer^b

Ref.

0.66 (0.46, 0.95)

0.61 (0.39, 0.95)

0.042

Gallbladder and extrahepatic bile duct cancer^c

Ref.

2.27 (0.65, 7.92)

1.67 (0.38, 7.31)

0.413

Leukemia and lymphoma

Ref.

0.90 (0.51, 1.59)

0.76 (0.36, 1.57)

0.754

Endometrial and cervical cancer^a

Ref.

0.63 (0.29, 1.34)

0.62 (0.27, 1.43)

0.452